Treatment of Prolactinoma in Giant Pituitary Adenoma (>40 mm) with Very High Prolactin Levels
This protocol addresses the management of a giant prolactinoma — a prolactin-secreting pituitary adenoma exceeding 40 mm in diameter with notable extrasellar extension and markedly elevated serum prolactin.
Clinical Scenario
Giant prolactinomas are defined by a diameter greater than 40 mm with notable extrasellar extension and very high serum prolactin levels (usually >1,000 µg/l), without concomitant GH or ACTH secretion. They are rare and predominantly observed in men.
Treatment Approach
Despite their aggressive radiological appearance, giant prolactinomas are mostly benign and typically respond well to dopamine agonist therapy. Medical management is the cornerstone of care — the specific agent, sequence, and monitoring details are in the full structured protocol.
Treatment Goals
- Improved visual fields
- Normalized serum prolactin levels
- Meaningful reduction in adenoma volume with notable mass size reduction
References
DOI: 10.1038/s41574-023-00886-5
- Giant prolactinomas are defined as those with a diameter >40 mm with notable extrasellar extension, very high serum levels of prolactin (usually >1,000 µg/l) and no concomitant GH or ACTH secretion.
- Giant prolactinomas are rare and are predominantly observed in men; as they usually respond well to dopamine agonist therapy, they should be managed medically (strong).
- Despite their aggressive appearance, these adenomas are mostly benign and respond well to cabergoline.
- High dopamine agonist efficacy is maintained in patients with a giant prolactinoma, with improved visual fields reported in 97% of patients, normalized serum levels of prolactin in 60% and reduced adenoma volume in 74%.
- Neurological symptoms improve in most patients with a notable mass size reduction, and prolactin serum levels normalize in up to 70% of patients.
View source ↗